Literature DB >> 21392250

Societal costs of prescription opioid abuse, dependence, and misuse in the United States.

Howard G Birnbaum1, Alan G White, Matt Schiller, Tracy Waldman, Jody M Cleveland, Carl L Roland.   

Abstract

OBJECTIVES: The objective of this study was to estimate the societal costs of prescription opioid abuse, dependence, and misuse in the United States.
METHODS: Costs were grouped into three categories: health care, workplace, and criminal justice. Costs were estimated by 1) quantity method, which multiplies the number of opioid abuse patients by cost per opioid abuse patient; and 2) apportionment method, which begins with overall costs of drug abuse per component and apportions the share associated with prescription opioid abuse based on relative prevalence of prescription opioid to overall drug abuse. Excess health care costs per patient were based on claims data analysis of privately insured and Medicaid beneficiaries. Other data/information were derived from publicly available survey and other secondary sources.
RESULTS: Total US societal costs of prescription opioid abuse were estimated at $55.7 billion in 2007 (USD in 2009). Workplace costs accounted for $25.6 billion (46%), health care costs accounted for $25.0 billion (45%), and criminal justice costs accounted for $5.1 billion (9%). Workplace costs were driven by lost earnings from premature death ($11.2 billion) and reduced compensation/lost employment ($7.9 billion). Health care costs consisted primarily of excess medical and prescription costs ($23.7 billion). Criminal justice costs were largely comprised of correctional facility ($2.3 billion) and police costs ($1.5 billion).
CONCLUSIONS: The costs of prescription opioid abuse represent a substantial and growing economic burden for the society. The increasing prevalence of abuse suggests an even greater societal burden in the future. Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21392250     DOI: 10.1111/j.1526-4637.2011.01075.x

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  214 in total

1.  Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Irma H Benedek; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-06-20       Impact factor: 4.492

2.  Gender and nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions - III.

Authors:  Bradley T Kerridge; Tulshi D Saha; S Patricia Chou; Haitao Zhang; Jeesun Jung; W June Ruan; Sharon M Smith; Boji Huang; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2015-09-02       Impact factor: 4.492

Review 3.  Alcohol and Opioid Use, Co-Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review.

Authors:  Katie Witkiewitz; Kevin E Vowles
Journal:  Alcohol Clin Exp Res       Date:  2018-02-06       Impact factor: 3.455

4.  Recreational marijuana legalization and prescription opioids received by Medicaid enrollees.

Authors:  Yuyan Shi; Di Liang; Yuhua Bao; Ruopeng An; Mark S Wallace; Igor Grant
Journal:  Drug Alcohol Depend       Date:  2018-10-25       Impact factor: 4.492

5.  Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.

Authors:  Roger D Weiss; Jennifer Sharpe Potter; David A Fiellin; Marilyn Byrne; Hilary S Connery; William Dickinson; John Gardin; Margaret L Griffin; Marc N Gourevitch; Deborah L Haller; Albert L Hasson; Zhen Huang; Petra Jacobs; Andrzej S Kosinski; Robert Lindblad; Elinore F McCance-Katz; Scott E Provost; Jeffrey Selzer; Eugene C Somoza; Susan C Sonne; Walter Ling
Journal:  Arch Gen Psychiatry       Date:  2011-11-07

6.  Age of initiation, psychopathology, and other substance use are associated with time to use disorder diagnosis in persons using opioids nonmedically.

Authors:  Ty S Schepis; Jahn K Hakes
Journal:  Subst Abus       Date:  2017-07-19       Impact factor: 3.716

7.  Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.

Authors:  Amanda J Abraham; Hannah K Knudsen; Traci Rieckmann; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2013-03       Impact factor: 2.582

8.  Impact of opioid use on health care utilization and survival in patients with newly diagnosed stage IV malignancies.

Authors:  Dylan Zylla; Grant Steele; Alice Shapiro; Sara Richter; Pankaj Gupta
Journal:  Support Care Cancer       Date:  2018-02-02       Impact factor: 3.603

9.  Can we build an efficient response to the prescription drug abuse epidemic? Assessing the cost effectiveness of universal prevention in the PROSPER trial.

Authors:  D Max Crowley; Damon E Jones; Donna L Coffman; Mark T Greenberg
Journal:  Prev Med       Date:  2014-02-09       Impact factor: 4.018

10.  The Impact of Policy Changes on Heroin and Nonmedical Prescription Opioid Use among an Incarcerated Population in Kentucky, 2008-2016.

Authors:  Amanda M Bunting; Grant Victor; Erika Pike; Michele Staton
Journal:  Crim Justice Policy Rev       Date:  2019-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.